Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
First Trust Advisors LP reduced its position in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 4.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,677 shares of the company's stock after selling 3,008 shares during the quarter. First Trust Advisors
American Capital Management Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 2.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 217,947 shares of the company's stock after selling 6,427 shares during the period. Medpace accounts
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Dimensional Fund Advisors LP cut its position in Medpace Holdings, Inc. (NASDAQ: MEDP) by 3.0% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 348,485 shares of the company's stock after selling 10,865 shares during the period. Dimensional Fund Advisors LP owned about
Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027.
First Trust Advisors LP reduced its position in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 4.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,677 shares of the company's stock after selling 3,008 shares during the quarter. First Trust Advisors
American Capital Management Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 2.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 217,947 shares of the company's stock after selling 6,427 shares during the period. Medpace accounts
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Dimensional Fund Advisors LP cut its position in Medpace Holdings, Inc. (NASDAQ: MEDP) by 3.0% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 348,485 shares of the company's stock after selling 10,865 shares during the period. Dimensional Fund Advisors LP owned about
Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Oncology bookings are robust, while cardiometabolic awards have declined; management expects mix normalization over the next year. Guidance is lifted on improved RFP trends, biotech funding breadth, and moderated cancellations, supporting growth momentum into 2027.
Arrowstreet Capital Limited Partnership grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 5.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 395,769 shares of the company's stock after buying an additional 20,736 shares during the quarter. Arrowstreet
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace Holdings Inc. (NASDAQ:MEDP) stock is trading higher on Thursday on better-than-expected second-quarter financial results and raised its fiscal 2026 guidance.
Medpace Holdings remains a "Buy" as Q2 2026 showed broad metric improvement and an inflection point in growth trajectory. The company's net book-to-Bill ratio rebounded to 1.13x, and backlog conversion rate rose to 24.1%, signaling strong future revenue visibility. Revenue grew 17.2% YoY to $707.3M, with EPS of $4.25 beating expectations; full-year 2026 guidance was raised to $2.805B–$2.885B.
Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcript
Medpace NASDAQ: MEDP reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings.
Medpace (MEDP) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.1 per share a year ago.
Medpace stock surged by double digits late Wednesday helped by a big bookings beat.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Revenue for the three months ended June 30, 2026 increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2026 increased 17.2% compared to the second quarter of 2025. Backlog as of June 30, 2026 in.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
On July 07, 2026, Medpace Holdings Inc (MEDP) shares fell 3.4% today to a current price of $546.29. The stock has experienced significant volatility, trading wi
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
In the closing of the recent trading day, Medpace (MEDP) stood at $543.57, denoting a +2.64% move from the preceding trading day.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Medpace (MEDP) reached $519.96 at the closing of the latest trading day, reflecting a +1.4% change compared to its last close.
On June 23, 2026, Medpace Holdings Inc (MEDP) shares rose 3.9% today, closing at $473.53. The stock has experienced a 52-week range of $305.69 to $628.92, refle
Medpace (MEDP) closed the most recent trading day at $461.6, moving 1.26% from the previous trading session.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you joi.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Medpace (MEDP) closed at $466.79 in the latest trading session, marking a +1.94% move from the prior day.
NEW YORK, June 8, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period").
NEW YORK--(BUSINESS WIRE)---- $MEDP #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The fir.
New York, New York--(Newsfile Corp. - June 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
RIDGEWOOD, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- RIDGEWOOD, N.J., June 8, 2026 (GLOBE NEWSWIRE) -- Safirstein Law LLC announces that a class action lawsuit has been filed on behalf of shareholders against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP).
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (âMedpaceâ or t
NEW YORK--(BUSINESS WIRE)---- $MEDP #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The fir.
San Diego, California--(Newsfile Corp. - June 8, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, all dates inclusive (the "Class Period"), have until today, Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v.
NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.
New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
MONDAY INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller
SAN DIEGO, June 6, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, all dates inclusive (the "Class Period"), have until this Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v.
Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
LOS ANGELES, June 5, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). IF YOU SUFFERED A LOSS ON YOUR MEDPACE INVESTMENTS, CLICK HERE BEFORE JUNE 8, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026. Medpace describes itself as a “clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.”For more informatio.
New York, New York--(Newsfile Corp. - June 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
New York, New York--(Newsfile Corp. - June 5, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 5, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Medpace Holdings, Inc. (NASDAQ: MEDP). Shareholders who purchased shares of MEDP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
Medpace Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MEDP PR Newswire
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc
LOS ANGELES, June 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MEDP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.
Promise vs. Reality: The Medpace Performance Gap NEW YORK, June 4, 2026 /PRNewswire/ -- SueWallSt highlights the contrast between Medpace Holdings Inc.'s (NASDAQ: MEDP) promises and results.
Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medpace (MEDP) To Contact Him Directly To Discuss Their Options If you purchased or acquired Medpace common stock between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Bragar Eagel and Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medpace (MEDP) To Contact Him Directly To Discuss Their Options
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit
NEW YORK, June 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. So what: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
LOS ANGELES, June 04, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.
LOS ANGELES, June 04, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before June 5, 2026.
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, all dates inclusive (the “Class Period”), have until Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v.
[url="]The Law Offices of Frank R. Cruz[/url] reminds investors of the upcoming June 8, 2026 deadline to participate as a lead plaintiff in the securities fraud
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 8, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON MEDPACE HOLDINGS, INC. (MEDP), CLICK HERE TO PARTICIPATE IN TH.
New York, New York--(Newsfile Corp. - June 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
BENSALEM, Pa., June 3, 2026 /PRNewswire/ -- The Law Offices of Howard G.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 3, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Important Information Regarding Section 20(a) Individual Liability Claims NEW YORK, June 3, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Medpace Holdings Inc. (NASDAQ: MEDP) of a pending securities class action naming senior executives as individual defendants. Class Period: April 22, 2025 through February 9, 2026.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
LOS ANGELES, June 3, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before June 5, 2026.
Medpace Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MEDP PR Newswire
LOS ANGELES, June 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MEDP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Medpace (MEDP) closed at $445.59 in the latest trading session, marking a -1.3% move from the prior day.
New York, New York--(Newsfile Corp. - June 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
LOS ANGELES, June 02, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 8, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the “Class Period”).
LOS ANGELES, June 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Medpace Holdings, Inc., (“Medpace” or the "Company") (NASDAQ: MEDP) investors of a class action on behalf of investors that bought securities between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”). Medpace investors have until June 8, 2026 to file a lead plaintiff motion.
NEW YORK, June 2, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Medpace Holdings, Inc. (NASDAQ: MEDP). Shareholders who purchased shares of MEDP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.
The trading activity of members of Congress continues to be closely monitored by investors, especially when the moves include Magnificent Seven or large technology stocks. One member of Congress recently sold some Magnificent Seven stocks.
NEW YORK, June 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. So what: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA
New York, New York--(Newsfile Corp. - June 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period").
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 1, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
LOS ANGELES, June 01, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Medpace Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MEDP PR Newswire
LOS ANGELES, June 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MEDP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
LOS ANGELES, June 1, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before June 5, 2026.
New York, New York--(Newsfile Corp. - May 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 31, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
New York, New York--(Newsfile Corp. - May 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
San Diego, California--(Newsfile Corp. - May 29, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, all dates inclusive (the "Class Period"), have until Monday, June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v.
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline.
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.
New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Medpace securities between April 22, 2025 and February 9, 2026, both dates inclusive (the “Class Period”).
